Breaking News

Cumberland Pharma Acquires Astellas’ Vaprisol

By Kristin Brooks | March 3, 2014

Assumes responsibility for marketing, distribution and manufacture

Cumberland Pharmaceuticals, Inc. has acquired Vaprisol from Astellas Pharma US, Inc. Vaprisol is one of two branded prescription products indicated for the treatment of hyponatremia, an electrolyte disturbance associated with congestive heart failure, liver failure, kidney failure and pneumonia. The product was developed and registered by Astellas and was launched in 2006. 
 
Cumberland will assume full responsibility for marketing, distribution and manufacture. Cumberland will promote Vaprisol in the U.S. through its hospital sales force, which also features its Caldolor and Acetadote brands.
 
"We believe Vaprisol is an excellent strategic fit with our focus on hospital acute care," said A.J. Kazimi, chief executive officer of Cumberland Pharmaceuticals. "Our immediate plan for Vaprisol is to ensure a smooth transition of the product supply and medical support to current users of the brand. We will then launch our hospital promotion support and are very optimistic about the opportunity that Vaprisol will offer Cumberland."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important